Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

Participants were broken into two cohorts. The first cohort received one of three doses of PCRX-201. The second cohort received concurrent pretreatment with an intraarticular corticosteroid ...

Detailed price information for Igm Biosciences Inc (IGMS-Q) from The Globe and Mail including charting and trades.

Communication is key to a well-functioning school environment, and posters play a vital role in spreading information ...

Posters will be presented at the 2024 Annual Meeting of the ... By employing a multi-specific Switch-DARPin, Molecular Partners aims to bring additional dimensions of safety and potency to the ...

STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of ...

A first-of-its-kind algorithm developed at Georgia Tech is helping scientists study interactions between electrons. This ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC <a target=_blank href=http ...

To ensure businesses are prepared for the 2025 legislative landscape, the SCV Chamber is set to present the only local, ...

The Santa Clarita Valley Chamber of Commerce has announced its annual 2025 Employment Law Update, taking place on Thursday, ...